If the tumor stage is graded as IIIa or IIIb based on postoperative pathological staging, with an epidermal growth factor receptor (EGFR) gene mutation or ALK rearrangement, oral targeted drug therapy can be considered as a postoperative adjuvant treatment29 to avoid chemotherapy‐associated infection and repeated hospital consultations. The gene discussed is EGFR; the disease is infection.